Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 20;30(2):127-130.
doi: 10.3760/cma.j.cn501113-20220108-00008.

[Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure]

[Article in Chinese]
L Zhou  1 , Y Chen  1
Affiliations

[Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure]

[Article in Chinese]
L Zhou et al. Zhonghua Gan Zang Bing Za Zhi. .

Abstract
in English, Chinese

Artificial liver is one of the effective methods to treat liver failure. Patients with liver failure are critically ill and have great individualized differences. Therefore, the specific program for the treatment of liver failure with artificial liver should be individualized. The commonly used non-biological artificial liver models include simple plasmapheresis, double filtration plasmapheresis, plasma filtration with dialysis, double plasma molecular adsorption system, molecular absorbent recirculating system, hemodiafiltration, continuous venovenous hemodiafiltration, hybrid, etc. The curative effect should be properly judged from patient's symptoms, laboratory test indicators, survival rate and other aspects after artificial liver therapy.

人工肝是治疗肝衰竭的有效方法之一。肝衰竭患者病情危重、病情个体化差异较大，人工肝治疗肝衰竭的具体方案应个体化。常用的非生物型人工肝模式包括单纯血浆置换、双重滤过血浆置换、血浆透析滤过、双重血浆分子吸附系统、分子吸附再循环系统、血液透析滤过、连续性静脉-静脉血液透析滤过、组合模式人工肝治疗等。在人工肝治疗后，应从患者症状、实验室检查指标、生存率等方面对其疗效做出恰当的判断。.

Keywords: Artificial liver treatment; Effect; Hybrid mode; Liver failure; Therapy.

PubMed Disclaimer

Conflict of interest statement

所有作者均声明不存在利益冲突

References

    1. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组 .肝衰竭诊治指南(2018年版)[J].中华肝脏病杂志, 2019, 27(1):18-26. DOI: 10.3760/cma.j.issn.1007-3418.2019.01.006. - DOI
    1. 段 钟平.防微杜渐，关注肝衰竭前期诊疗[J].中华肝脏病杂志, 2020, 28(04):289-291. DOI: 10.3760/cma.j.cn501113-20200318-00124. - DOI
    1. 李 爽, 周 莉, 刘 静, et al.血浆置换应用羟乙基淀粉替代部分血浆治疗肝衰竭的临床观察[J].胃肠病学和肝病学杂志, 2019, 28(7):735-739. DOI: 10.3969/j.issn.1006-5709.2019.07.004. - DOI
    1. 李 爽, 刘 静, 陈 煜.非生物型人工肝在肝衰竭中的临床应用及进展[J].临床肝胆病杂志, 2019, 35(9):1909-1915. DOI: 10.3969/j.issn.1001-5256.2019.09.004. - DOI
    1. 李 爽, 陈 煜.血浆紧缺情况下非生物型人工肝治疗新模式的探讨[J].临床肝胆病杂志, 2017, 33(9):1687-1692. DOI: 10.3969/j.issn.1001-5256.2017.09.012. - DOI - PubMed